"In a high risk, elderly patient population with significant
comorbidities, sequential R-CHOP followed by radioimmunotherapy resulted in
excellent complete response and overall and progression-free survival
rates," concluded Hamlin. "This approach is now the focus of an
international phase III study."

"Improvement of relapse-free survival in these patients is an important
unmet need since the outcome is poor for patients who relapse with this
disease and who cannot tolerate intensive salvage therapy and stem cell
transplantation," said Jack W. Singer, M.D., Chief Medical Officer at CTI.
"The survival data from this study are highly encouraging compared to
historical data and provide the rationale for a registration-directed
randomized trial of Zevalin consolidation in higher risk patients with
DLBCL."

Results of the Study

Historical studies provided as background in the presentation indicate
that approximately 50 percent of elderly patients with high risk diffuse
large B-cell lymphoma (DLBCL) relapse after treatment with R-CHOP.
Treatment options for patients who are ineligible for autologous stem cell
transplant are limited. In this analysis, of the 63 patients enrolled on
the study, 39 patients had been treated with Zevalin. The median age is 75
years (range 62-86); Karnofsky performance status was <80 percent in 59
percent of patients with a median performance status of 70 percent;
prognostic score was high-intermediate/high in 53 percent and 47 percent of
patients, respectively. Moderate or high impact comorbidity is present in
86 percent. In the intent-to-treat population, progression-free (PFS) and
overall survival (OS) were 59 percent and 65 percent, respectively, at 22
months. In the 39 patients who received Zevalin, PFS and OS were 78 percent
and 82 percent, respectively, at 26 months. Responses improved in 11
patients who received Zevalin, with eight patients improving from an
unconfirmed (CRu) to a confirmed complete response (CR) and three patients
improving from a partial response (PR) to a CR/CRu. The side effects
reported included blood count suppression: 26 percent and 36 percent grade
3/4 neutropenia, 15 percent grade 3 anemia, and 36 percent and 31 percent
grade 3/4 thrombocytopenia. Six patients had delayed blood count recovery
for more than 12 weeks. One patient developed myelodysplasia and two
patients died after Zevalin was given, one from a suspected brain
hemorrhage and one from congestive heart failure.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called
radioimmunotherapy and is indicated as part of the Zevalin therapeutic
regimen for treatment of relapsed or refractory, low-grade or follicular
B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory
follicular NHL. It was approved by the FDA in February of 2002 as the first
radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have
occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin
administration results in severe and prolonged cytopenias in most patients.
Severe cutaneous and mucocutaneous reactions have been reported. The most
serious adverse reactions of the Zevalin therapeutic regimen were primarily
hematologic, including neutropenia, thrombocytopenia, and anemia.
Infusion-related toxicities were associated with pre-administration of
rituximab. The risk of hematologic toxicity correlated with the degree of
bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute
myelogenous leukemia was observed in 2 percent of patients (8 to 34 months
after treatment). Zevalin should only be used by health care professionals
qualified by training and experience in the safe use of radionuclides.

Headquartered in Seattle, CTI is a biopharmaceutical company committed
to developing an integrated portfolio of oncology products. For additional
information, please visit http://www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results. Specifically, the risks and
uncertainties that could affect the development of Zevalin include risks
associated with preclinical and clinical developments in the
biopharmaceutical industry in general and with Zevalin in particular
including, without limitation, the potential failure of Zevalin to prove
safe and effective for treatment of high risk elderly DLBCL, determinations
by regulatory, patent and administrative governmental authorities,
competitive factors, technological developments, costs of developing,
producing and selling Zevalin, and the risk factors listed or described
from time to time in the Company's filings with the Securities and Exchange
Commission including, without limitation, the Company's most recent filings
on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does
not intend to update or alter its forward-looking statements whether as a
result of new information, future events, or otherwise.

(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...

(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...

(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...

(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...

(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...